Cannabinoids may help treat fatty liver disease
Researchers at Hebrew University of Jerusalem found that CBD and CBG, two compounds from cannabis, can lower liver fat and reduce harmful lipids linked to inflammation, while also helping with blood sugar control.
Their findings, published March 6 in the British Journal of Pharmacology, suggest these cannabinoids could be useful for treating fatty liver disease (MASLD).
Both compounds reduced harmful lipids in the liver
In mouse studies with high-fat diets, both CBD and CBG reduced harmful lipids (e.g., triglycerides and ceramides) in the liver.
They also boosted energy reserves in the liver, which helps it handle metabolic stress better.
CBG showed even stronger results than CBD
CBG showed even stronger results than CBD: it lowered body fat, bad cholesterol (LDL), and improved insulin sensitivity more effectively.
Professor Joseph Tam shared that their research identifies a new mechanism for how these compounds boost liver health.
The team has patented their CBD and CBG combo and aims to advance to clinical trials.